| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2021 | PFE Pfizer Inc | Damico Jennifer B.58 | SVP &Controller | Sell | 2,500 | $40.82 | $102,050.00 | -15.4% | +16.5% | +25.5% | |
| May 5, 2021 | BMY Bristol Myers Squibb Co | Vessey Rupert53 | EVP, Research &Early Dev. | Sell | 30,546 | $64.29 | $1,963,802.34 | -40.4% | +7.9% | +21.7% | |
| May 4, 2021 | TAK Takeda Pharmaceutical Co Ltd | Takeda Pharmaceutical Co Ltd70 | 10% Owner | Sell | 33,992 | $37.00 | $1,257,848.68 | -0.5% | +0.8% | -7.4% | |
| May 3, 2021 | ALKS Alkermes Plc. | Jackson Blair Curtis | EVP, Chief Operating Officer | Sell | 34,503 | $22.18 | $765,155.78 | -33.6% | +21.7% | +31.0% | |
| May 3, 2021 | ZTS Zoetis Inc. | Kelly Robert Edward | Executive Vice President | Sell | 2,053 | $174.70 | $358,659.10 | -19.8% | +15.5% | +0.5% | |
| May 3, 2021 | ZTS Zoetis Inc. | Chen Heidi C.47 | Executive Vice President | Sell | 12,238 | $175.01 | $2,141,772.38 | -33.2% | +15.5% | +0.5% | |
| Apr 30, 2021 | LLY Eli Lilly & Co | Tai Jackson P | Director | Buy | 1,366 | $182.84 | $249,759.34 | +1.1% | +34.8% | +62.3% | |
| Apr 29, 2021 | BUDZ Weed, Inc. | Breen Nicole M | Secretary/ Treasurer | Sell | 30,000 | $0.54 | $16,085.00 | - | - | - | |
| Apr 28, 2021 | LLY Eli Lilly & Co | Zakrowski Donald A | Chief Accounting Officer | Sell | 3,000 | $181.38 | $544,140.00 | -33.4% | +35.5% | +67.1% | |
| Apr 22, 2021 | BUDZ Weed, Inc. | Breen Nicole M | Secretary/ Treasurer | Sell | 31,000 | $0.53 | $16,480.00 | - | - | - | |
| Apr 21, 2021 | ZTS Zoetis Inc. | Chen Heidi C.47 | Executive Vice President | Sell | 11,637 | $170.14 | $1,979,919.18 | -32.1% | +17.8% | +9.2% | |
| Apr 20, 2021 | LFCR Lifecore Biomedical, Inc. \de\ | Walsh Patrick D52 | Director | Buy | 10,000 | $11.26 | $112,600.00 | +33.3% | +9.7% | -2.9% | |
| Apr 19, 2021 | ALKS Alkermes Plc. | Dixon Wendy L | Director | Sell | 25,000 | $20.00 | $500,120.00 | -40.6% | +16.5% | +42.0% | |
| Apr 19, 2021 | LFCR Lifecore Biomedical, Inc. \de\ | Morberg John D | Chief Financial Officer | Buy | 2,000 | $11.05 | $22,100.00 | +11.5% | +9.0% | -5.4% | |
| Apr 19, 2021 | ALKS Alkermes Plc. | Brown Iain Michael | SVP, Chief Financial Officer | Sell | 35,000 | $20.00 | $699,917.90 | -26.6% | +16.5% | +42.0% | |
| Apr 16, 2021 | LFCR Lifecore Biomedical, Inc. \de\ | Morberg John D | Chief Financial Officer | Buy | 2,000 | $11.08 | $22,160.00 | +13.0% | +2.8% | -8.7% | |
| Apr 16, 2021 | LNTH Lantheus Holdings, Inc. | Duffy Michael P | SVP And General Counsel | Sell | 7,500 | $21.75 | $163,125.00 | -6.4% | +18.3% | +180.1% | |
| Apr 15, 2021 | ALKS Alkermes Plc. | Hopkinson Craig C.54 | EVP R&D, Chief Medical Officer | Sell | 28,920 | $19.72 | $570,287.94 | -100% | +21.2% | +48.5% | |
| Apr 15, 2021 | ZTS Zoetis Inc. | Trawicki Roman48 | Executive Vice President | Sell | 4,491 | $165.00 | $741,015.00 | -65.0% | +21.8% | +13.8% | |
| Apr 15, 2021 | LFCR Lifecore Biomedical, Inc. \de\ | Morberg John D | Chief Financial Officer | Buy | 2,000 | $10.98 | $21,960.00 | +14.9% | -0.3% | -9.2% | |
| Apr 14, 2021 | LFCR Lifecore Biomedical, Inc. \de\ | Bolles Albert D. | Chief Executive Officer | Buy | 9,000 | $10.61 | $95,490.00 | +24.9% | +7.3% | -2.7% | |
| Apr 14, 2021 | LFCR Lifecore Biomedical, Inc. \de\ | Hall James G | Vice President | Buy | 10,000 | $10.62 | $106,200.00 | +34.3% | +7.3% | -2.7% | |
| Apr 14, 2021 | LFCR Lifecore Biomedical, Inc. \de\ | Morberg John D | Chief Financial Officer | Buy | 2,000 | $10.64 | $21,280.00 | +17.5% | +7.3% | -2.7% | |
| Apr 14, 2021 | SUPN Supernus Pharmaceuticals, Inc. | Martin Tami Tillotson54 | Sr. V.p., Regulatory Affairs | Sell | 6,250 | $30.98 | $193,639.38 | -3.5% | -12.6% | -2.4% | |
| Apr 13, 2021 | PCRX Pacira Biosciences, Inc. | Williams Kristen Marie76 | Chief Administrative Officer | Sell | 21,823 | $66.95 | $1,461,068.50 | -27.8% | -16.8% | +11.1% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.